News
Publications
- Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy. Van der Vreken A. et al. Journal of Immunotherapy of Cancer 2025.
- De ontwikkeling van mRNA-vaccins voor kankerbestrijding.
Rein Verbeke, Joline Ingels, Bart Vandekerckhove, Ine Lentacker. Onco-Hemato 2025 - mRNA galsomes vaccine protects budgerigars against virulent Chlamydia psittaci challenge.
De Meyst A. et al. Vaccines 2025 - Current state of mRNA vaccine development against Mycobacterium tuberculosis.
Aernout I. et al. Trends in mRNA vaccine research 2025 - A historical overview on mRNA vaccine development.
Verbeke R. et al. Trends in mRNA vaccine research 2025 - Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria.
Meulewaeter S. et al. Journal of Controlled Release 2024 - The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs.
D’Haese S. et al. Molecular Therapy Nucleic Acids 2024 - Considerations on the design of lipid-based mRNA vaccines against cancer.
Meulewaeter S. et al. Journal of Molecular Biology 2024 - Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures.
Meulewaeter S et al., Journal of Controlled Release 2023 - Innate immune mechanisms of mRNA vaccines.
Verbeke R. et al. Immunity 2022 - Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes.
Mayer R.L. et al., Nature communications 2022 - mRNA-lipid nanoparticle COVID-19 vaccines : structure and stability.
Schoenmaeker L. et al. International Journal of Pharmaceutics 2021
Nanomedicine Centre 